Jessica Thompson
@jlthompsonmd
Breast Surgical Oncology @CorewellHealth ~ Training @SpectrumHealth @UMichSurgery ~ Wife and Mom ~ Tweets are my own
ID: 1464415288640913420
27-11-2021 02:07:38
56 Tweet
120 Followers
226 Following
New editorial from Anna Weiss and Tari King MD in Annals of Surgical Oncology. ➡️➡️ Local Regional Recurrence Rates Are Low Following Neoadjuvant Endocrine Therapy: What Are the Remaining Barriers to its Widespread Adoption? ⬇️⬇️Read fulltext here: rdcu.be/c2UAz
🔊⚠️🔊⚠️ In the latest poll, 70% considered the use of primary sustained endocrine therapy (ET) in HR+ HER2- in #breastcancer patients older than 70yrs. Let’s check recent evidence on that published at Annals of Surgical Oncology! 🧵🧵🧵
Excellent new podcast from the Society of Surgical Oncology Fellows & Young Attendings Subcommittee — tips on preparing for the transition from trainee to faculty practice! Kimberly Washington, MD @bsparkmanMD Jennifer Tseng #SSO_FYAS surgonctoday.libsyn.com/mastering-the-…
Calling all TRAINEES attending Society of Surgical Oncology #SSO2023 - check out the Trainees Lounge, Rm 210. New this year we will have representatives from many CGSO and Breast Fellowship Programs to learn about the programs and #network! See thread below for the programs participating:
Dr. Anita Mamtani Memorial Sloan Kettering Cancer Center presents on axillary management in cT1N0 TNBC & Her2+ breast ca. These patients may be safely selected to undergo upfront surgery w/o concern that many will be node positive & would have benefited from de-escalation of axilla w/ NACT. #SSO2023
Strong start to #ASBRS2023 with thoughtful presentations highlighting controversial issues in breast surgery ASBrS Puneet Singh, MD FACS jennifer bellon
.Clara R. Farley beautifully presents MD Anderson Cancer Center study on factors predicting 4 or more positive nodes in cN0 HR+/Her2- breast cancer. Important data as we try to better predict nodal burden which can impact systemic therapy decisions #ASBrS23 ASBrS
Which should be the duration of adjuvant endocrine treatment for early-stage HR+ breast cancer? Dr. Michael Gnant nicely recapitulates the evidence & highlights the recent votes by the St. Gallen panel, with fairly clear answers. #ASCO23
#ASCO23 #BreastCancer Poster Session: ASCENT-05/OptimICE-RD: Phase 3 study of adjuvant sacituzumab govitecan + pembro vs pembro ± capecitabine in patients with #TNBC and residual disease after neoadjuvant therapy and surgery. Sara Tolaney Lisa Carey, MD, ScM, FASCO meetings.asco.org/2023-asco-annu…
🔥📄 Hot off the Journal of Clinical Oncology press‼️ The ASCO guideline on germline testing in patients with #BreastCancer 👏Congrats to all on this important work! Filipa Lynce, MD, FASCO 🇵🇹 🇺🇸 Isabelle Bedrosian @MarkRobsonMD Sid Yadav MD, FACP Maria Isabel Achatz MD PhD Judy Boughey G Curigliano MD PhD Sue Friedman pubmed.ncbi.nlm.nih.gov/38175972/